Free Access
Volume 53, Number 2, April-June 2018
Page(s) 101 - 105
Published online 04 May 2018
  • Berrington de Gonzalez AB, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E. 2011. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 12: 353–360. [CrossRef] [PubMed] [Google Scholar]
  • Chargari C, Goodman KA, Diallo I, Guy JB, Rancoule C, Cosset JM, Deutsch E, Magne N. 2016. Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models? Cancer Metastasis Rev. 35(2): 277–288. [CrossRef] [PubMed] [Google Scholar]
  • Colin C, Foray N, Di Leo G, Sardanelli F. 2017. Radiation induced breast cancer risk in BRCA mutation carriers from low-dose radiological exposures: a systematic review. Radioprotection 52: 231–240. [CrossRef] [EDP Sciences] [Google Scholar]
  • Cosset JM, Henry-Amar M, Dietrich PY, Socié G, Girinsky T, Hayat M, Tubiana M. 1992. Tumeurs solides secondaires après radiothérapie de la maladie de Hodgkin : expérience de l’institut Gustave-Roussy. Bull. Cancer 79(4): 387–388. [PubMed] [Google Scholar]
  • Cosset JM, Chargari C, Demoor C, Giraud P, Helfre S, Mornex F, Mazal A. 2016. Prévention des cancers radio-induits. Cancer Radiother. 20(Suppl.): S61–S68. [CrossRef] [PubMed] [Google Scholar]
  • Foray N, Bourguignon M, Hamada N. 2016. Individual response to ionizing radiation. Mutat. Res. 770: 369–386. [CrossRef] [PubMed] [Google Scholar]
  • Gray LH. 1957. Radiobiology and cancer. Nature 179(4568): 991–994. [CrossRef] [PubMed] [Google Scholar]
  • Hall E. 2006. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 65(1): 1–7. [CrossRef] [PubMed] [Google Scholar]
  • Koshy M et al. 2012. Declining use of radiotherapy in stages I and II Hodgkin’s disease and its effect on survival and secondary malignancies. Int. J. Radiat. Oncol. Biol. Phys. 82: 619–620. [CrossRef] [PubMed] [Google Scholar]
  • Kry SF, Bednarz B, Howell RM, Dauer L, Followill D, Klein E, Paganetti H, Wang B, Wuu CS, George Xu X. 2017. AAPM TG 158: measurement and calculation of doses outside the volume from external-beam radiation therapy. Med. Phys. 44(10): e391–e429. [CrossRef] [PubMed] [Google Scholar]
  • Langballe R, Olsen JH, Andersson M, Mellemkjær L. 2011. Risk for second primary non-breast cancer in pre- and postmenopausal women with breast cancer not treated with chemotherapy, radiotherapy or endocrine therapy. Eur. J. Cancer 47: 946–952. [CrossRef] [PubMed] [Google Scholar]
  • Little MP. 2001. Comparison of the risks of cancer incidence and mortality following radiation therapy for benign and malignant disease with the cancer risks observed in the Japanese A-bomb survivors. Int. J. Radiat. Biol. 77(4): 431–464. [CrossRef] [PubMed] [Google Scholar]
  • Peiffert D, Simon JM, Eschwege F. 2007. Epinal radiotherapy accident: passed, present, future. Cancer Radiother. 11(6-7): 309–312. [CrossRef] [PubMed] [Google Scholar]
  • Schneider U. 2011. Modeling the Risk of secondary malignancies after radiotherapy genes. Basel 2(4): 1033–1049. [Google Scholar]
  • Schneider U, Walsh L. 2008. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat. Environ. Biophys. 47(2): 253–63. [CrossRef] [PubMed] [Google Scholar]
  • Somers R, Henry-Amar M, Meerwaldt JH, Carde P. 1990. Treatment strategy in Hodgkin’s disease. John Libbey Eurotext. [Google Scholar]
  • Suit H, et al. 2007. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat. Res. 167: 12–42. [CrossRef] [PubMed] [Google Scholar]
  • Travis LB, et al. 2002. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J. Natl. Cancer Inst. 94(3): 182–192. [CrossRef] [PubMed] [Google Scholar]
  • Trott KR. 2017. Special radiobiological features of second cancer risk after particle radiotherapy. Phys. Med. 42: 221–227. [CrossRef] [PubMed] [Google Scholar]
  • Tubiana M. 2009. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother. Oncol. 91(1): 4–15. [CrossRef] [PubMed] [Google Scholar]
  • Zelefsky MJ, et al. 2012. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 83(3): 953–959. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.